Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Operating Expenses (2023 - 2025)

Zentalis Pharmaceuticals has reported Other Operating Expenses over the past 3 years, most recently at $4000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at $4000.0 for Q4 2025, down 99.89% from a year ago — trailing twelve months through Sep 2025 was $3.7 million (changed N/A YoY), and the annual figure for FY2024 was $3.7 million, down 91.8%.
  • Other Operating Expenses for Q4 2025 was $4000.0 at Zentalis Pharmaceuticals, up from -$4000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for ZNTL hit a ceiling of $45.6 million in Q2 2023 and a floor of -$4000.0 in Q1 2025.
  • Median Other Operating Expenses over the past 3 years was $1.9 million (2024), compared with a mean of $12.3 million.
  • Peak annual rise in Other Operating Expenses hit 99.89% in 2025, while the deepest fall reached 99.89% in 2025.
  • Zentalis Pharmaceuticals' Other Operating Expenses stood at $45.6 million in 2023, then plummeted by 91.8% to $3.7 million in 2024, then plummeted by 99.89% to $4000.0 in 2025.
  • The last three reported values for Other Operating Expenses were $4000.0 (Q4 2025), -$4000.0 (Q1 2025), and $3.7 million (Q4 2024) per Business Quant data.